FDA panel recommends approval of deferiprone

Shuchman, Miriam
November 2011
CMAJ: Canadian Medical Association Journal;11/8/2011, Vol. 183 Issue 16, pE1159
Academic Journal
The article reports on the launch of the oral iron chelator drug deferiprone by the U.S. Food and Drug Administration (FDA). It mentions that the drug is used for the treatment of patients with transfusion-related iron overload when other similar drugs fail. It also notes that the drug is effective in lowering levels of iron.


Related Articles

  • FDA approves deferiprone for patients with iron overload.  // Hem/Onc Today;11/10/2011, Vol. 12 Issue 21, p19 

    The article reports that deferipone has received approval from the U.S. Food and Drug Administration (FDA) to treat transfusional iron overload in patients with thlassemia who have exhibited inadequate responses to prior chelation therapy.

  • Controversial Chelator Approved. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;11/23/2011, Vol. 306 Issue 20, p2207 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to deferiprone as a treatment option for iron overload in patients with thalassemia.

  • News Briefs.  // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1499 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new formulation of docetaxel and a needleless intravenous (i.v.) connector with chlorhexidine and silver and zero-fluid displacement.

  • Slew of approvables.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p27 

    Lists several approval drugs by the U.S. Food and Drug Administration. Ranexa to treat chronic angina; Insulin determir, a long-acting form of the diabetes drug; Fortament, an extended-release product to lower blood glucose.

  • FDA actions in brief.  // Formulary;Feb2010, Vol. 45 Issue 2, p42 

    The article discusses news briefs about drugs approved by the U.S. Food and Drug Administration (FDA). The drugs include dalfampridine extended release tablets, tocilzumab and morphine sulfate oral solution.

  • Pipeline preview.  // Formulary;Apr2010, Vol. 45 Issue 4, p113 

    The article offers U.S. Food & Drug Administration (FDA) drug approval news briefs. Miglustat has been approved for the treatment of Niemann-Pick type C disease, pirfenidone has been recommended for approval to improve lung function and pixantrone has been recommended not to be approved.

  • FDA actions in brief.  // Formulary;Apr2010, Vol. 45 Issue 4, p114 

    The article presents a list of drugs approved by the U.S. Food & Drug Administration (FDA) including doxepin for the treatment of insomnia, adapalene lotion for the treatment of acne and somatropin injection for the treatment of growth hormone disorders.

  • New molecular entities/biologics.  // Formulary;Feb2003, Vol. 38 Issue 2, p78 

    Reports on drugs approved by the U.S. Food and Drug Administration as of February 2003. Extraneal; Humira.

  • FDA Drug Approvals.  // Formulary;Jul2003, Vol. 38 Issue 7, p392 

    Reports on the U.S. Food and Drug Administration's approval of various drugs, as of July 2003. Boniva; Xolair; FluMist.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics